Lilly starts second COVID-19 antibody test with partner Junshi Biosciences, eyes combo trials Flu shot makers gear up—and get creative—for a critical vaccination season As docs join protests across the country, AMA board pledges action against racism, police brutality Researchers find blood profile for screening severe COVID-19 cases from mild ones COVID-19 could cost insurers up to $547B through 2021: report Biopharma roundup: FDA official quits 'Warp Speed' over political pressure; BARDA expands Moderna deal Healthcare roundup: Molina extends cost-sharing waivers; U.S. shutdowns prevented 60M coronavirus infections, study finds As COVID-19 social media fatigue sets in, pharma begins to restart other health conversations Oxford Biomedica snags manufacturing equipment to ramp up production of COVID-19 vaccine Banner Health combats growing spike of COVID-19 cases in Arizona after stay-at-home order lifted FDA revokes authorization for decontaminating and reusing Chinese-made N95 respirator masks Sherlock Bio links with Danaher's IDT to supply its CRISPR-based coronavirus test FiercePharmaPolitics—FDA official leaves 'Warp Speed' to preserve independent regulatory power: report Featured Story | Monday, June 8, 2020 In just over a week Eli Lilly has gone from having nothing in the clinic to not one but now two antibody drugs targeting SARS-CoV-2 as it also eyes combining both, and more besides, for a more potent affect. read more |
| |
|---|
|
Top Stories Monday, June 8, 2020 With a second wave of coronavirus infection threatening the U.S. later this year, experts worry an influx of influenza patients and COVID-19 patients will hit U.S. hospitals at the same time. All the more reason to push flu shots—and top vaccine players Sanofi, Seqirus and GSK are working to ramp up for increased demand. read more Monday, June 8, 2020 In the face of growing unrest over racial inequality, the leadership of the nation's largest group representing physicians pledged action to confront systemic racism and police brutality. read more Monday, June 8, 2020 A simple blood test may be able to help clinicians understand why one patient with COVID-19 may develop severe, life-threatening complications while another may show barely any symptoms at all. read more Monday, June 8, 2020 The estimated costs for treating COVID-19 could add up as much as $547 billion for private insurers from 2020 to 2021 depending on the rate of infection, an updated report found. read more Monday, June 8, 2020 AstraZeneca approached Gilead Sciences about a megadeal last month, but analysts don't expect the U.S. biotech to bite. An FDA official reportedly left Operation Warp Speed to avoid political pressure. And BARDA secured packaging for COVID treatments and expanded its Moderna vaccine deal. read more Monday, June 8, 2020 Follow along with the latest COVID-19 news straight from the FierceHealthcare team. read more Monday, June 8, 2020 COVID-19 fatigue is setting in, and for pharma companies, that means an opportunity to return to social media messages on other health topics. Evoke Kyne and its new social media chief Kate Callan have been tracking social media conversations through the crisis and the latest numbers show a 65% drop in global conversations around COVID-19, from 204 million weekly mentions in mid-March to just 71 million in late May. read more Monday, June 8, 2020 In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, one of AstraZeneca's manufacturing partners has inked a deal to expand capacity to meet global demand. read more Monday, June 8, 2020 Banner Health is warning its Arizona hospitals are seeing a spike of COVID-19 cases after the state lifted its stay-at-home order. read more Monday, June 8, 2020 The FDA has revised its previous emergency authorizations for reprocessing N95 respirators, saying certain masks imported from China may not be able to withstand the decontamination process. read more Monday, June 8, 2020 Sherlock Biosciences will team up with Danaher’s Integrated DNA Technologies division to scale up the manufacturing of its CRISPR-based coronavirus diagnostic test in the coming weeks. read more Monday, June 8, 2020 As researchers worldwide race forward with COVID-19 vaccines, one influential expert has departed the United States’ Operation Warp Speed over concerns of political pressure playing into regulatory decisions. read more |
